Amptron Medical, Inc. appears in FDA device records as the applicant on a single premarket notification, K260226, received on 26 January 2026 and decided on 16 September 2026 with a Substantially Equivalent decision. The filing covers the ElintMAX Respiratory Monitor, also listed as ElintMAX Monitor A1, under product code BZK in the Anesthesiology advisory committee. The supplied collection holds one linked record, all under the 510(k) pathway, and the decision count for that collection is one Substantially Equivalent outcome. That count describes the supplied filings as of the snapshot date, not the company's total portfolio, sales or safety history. [1][5][7]

The K260226 filing and its regulatory scope

K260226 was submitted as a Traditional 510(k) with no third-party review, and the record notes that a summary is available rather than a statement. The device is classified as a Spirometer, Monitoring (W/Wo Alarm), device class 2, regulation number 868.1850, with the review panel recorded as Anesthesiology. The applicant contact listed on the filing is Nirav Patel, with a Carlsbad, California address on the submission. [1][5]

The decision description is Substantially Equivalent, dated 16 September 2026, roughly eight months after the January receipt date. Independent database entries reproduce the same identifiers: record K260226, applicant Amptron Medical, Inc., product code BZK, and the same decision date and decision code. The filing address is a submission detail and is not treated here as a verified corporate headquarters. [5][7]

Documented product and stated technology

The cleared device name in FDA records is ElintMAX Respiratory Monitor (ElintMAX Monitor A1). Amptron's own website describes ElintMAX as an FDA 510(k) cleared, non-invasive wearable respiratory monitor that combines a proprietary wearable sensor with signal processing to turn breathing-related signals into respiratory measurements and trends. The site refers to a Respiratory Vital Suite of respiratory parameters and lists respiratory rate among them. [1][4]

Those product descriptions come from the company's website and are attributed there; the FDA record establishes the clearance and classification, not the performance of the sensor or the accuracy of any parameter. No clinical outcome data, patient-selection criteria or treatment guidance is documented in the public documents. [1][4]

Company identity and self-description

A LinkedIn company page under the name Amptron Medical Inc. describes a startup in the medical device industry developing a next-generation respiratory care platform aimed at improving global access to life-saving respiratory care. The same page lists a founding year of 2018, an employee count of 4, a size field of 2, a Carlsbad, California locality, a privately held type and a website of amptronmedical.com. These attributes are the publisher's own statements. [6]

The website carries the tagline Sensing the Unseen and lists contact details including info@amptronmed.com and a phone number, along with sections on the Elint series, technology, and an investment value model. No parent company, brand owner or corporate affiliate is verified in the public documents, so Amptron Medical, Inc. is treated only as the named FDA applicant. [4]

What the record does not establish

The public documents contain no recall entries and no post-market records for this applicant, and their absence is not evidence of safety performance. Commercial availability, customers, certifications, pricing and clinical validation are not documented. The single linked record and its one Substantially Equivalent decision describe the supplied collection at the snapshot date only. [1][5]